{"id":42043,"date":"2022-02-07T07:40:38","date_gmt":"2022-02-07T07:40:38","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=42043"},"modified":"2022-02-09T17:49:47","modified_gmt":"2022-02-09T17:49:47","slug":"us-fda-approves-2-monthly-dosing-option-for-long-acting-injectable-cabotegravir-rilpivirine","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/42043","title":{"rendered":"US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir\/rilpivirine"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBsubhead3authorcredit\"><strong><span lang=\"EN-US\">On 1 February 2022, the US FDA expanded the indication for long-acting cabotegravir and rilpivirine to allow two-months dosing.<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYFIRST\"><span lang=\"EN-US\">This now matches the indication approved by the EMA in Europe.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYFIRST\"><span lang=\"EN-US\">This was based on similar viral efficacy and tolerability in the phase 2b ATLAS-2M study where two-monthly injections were non-inferior to monthly dosing.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">References<\/span><\/p>\n<\/div>\n<div>\n<ol>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">ViiV press release. ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment. (1 February 2022).<br \/>\n<\/span><a href=\"https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2022\/january\/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months\">https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2022\/january\/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months<\/a><\/li>\n<li class=\"HTBBODYtext\">Overton E et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomized, multicentre, open-label, phase 3b non-inferiority<\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 1 February 2022, the US FDA expanded the indication for long-acting cabotegravir and rilpivirine to allow two-months dosing. This now matches the indication approved by the EMA in Europe. This was based on similar viral &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-42043","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=42043"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42043\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=42043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=42043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=42043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}